103 related articles for article (PubMed ID: 8290967)
21. IDA-FLAG regimen for the therapy of primary refractory and relapse acute leukemia: a single-center experience.
Yavuz S; Paydas S; Disel U; Sahin B
Am J Ther; 2006; 13(5):389-93. PubMed ID: 16988532
[TBL] [Abstract][Full Text] [Related]
22. Induction chemotherapy with idarubicin plus N4-behenoyl-1-beta-D-arabinofuranosylcytosine in acute myelogenous leukemia: a newly designed induction regimen--a prospective, cooperative multicenter study.
Park HS; Kim DW; Kim CC; Kim HK; Kim JS; Hwang TJ; Kim HJ; Kim HS; Song HS; Park JW; Ahn HS; Chung TJ; Cho KS; Lee KS; Choi YM
Semin Hematol; 1996 Oct; 33(4 Suppl 3):24-9. PubMed ID: 8916313
[TBL] [Abstract][Full Text] [Related]
23. Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study.
Lemoli RM; Visani G; Leopardi G; Motta MR; Rizzi S; Testoni N; Curti A; Tura S
Bone Marrow Transplant; 1999 Feb; 23(3):235-41. PubMed ID: 10084254
[TBL] [Abstract][Full Text] [Related]
24. A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group AML 97 Study.
Miyawaki S; Sakamaki H; Ohtake S; Emi N; Yagasaki F; Mitani K; Matsuda S; Kishimoto Y; Miyazaki Y; Asou N; Matsushima T; Takahashi M; Ogawa Y; Honda S; Ohno R;
Cancer; 2005 Dec; 104(12):2726-34. PubMed ID: 16284985
[TBL] [Abstract][Full Text] [Related]
25. Idarubicin in induction treatment of acute myeloid leukemia in the elderly.
Leoni F; Ciolli S; Nozzoli C; Marrani C; Caporale R; Ferrini PR
Haematologica; 1997; 82(5 Suppl):13-8. PubMed ID: 9402748
[TBL] [Abstract][Full Text] [Related]
26. Continuous infusion idarubicin and oral busulfan as conditioning for patients with acute myeloid leukemia aged over 60 years undergoing autologous stem cell transplantation.
Ferrara F; Palmieri S; Annunziata M; Viola A; Pocali B; Califano C; D'Arco AM; Mele G
Bone Marrow Transplant; 2004 Oct; 34(7):573-6. PubMed ID: 15258559
[TBL] [Abstract][Full Text] [Related]
27. Arsenic trioxide- and idarubicin-induced remissions in relapsed acute promyelocytic leukaemia: clinicopathological and molecular features of a pilot study.
Kwong YL; Au WY; Chim CS; Pang A; Suen C; Liang R
Am J Hematol; 2001 Apr; 66(4):274-9. PubMed ID: 11279639
[TBL] [Abstract][Full Text] [Related]
28. Idarubicin and cytosine arabinoside in the induction and maintenance therapy of high-risk myelodysplastic syndromes.
Invernizzi R; Pecci A; Rossi G; Pelizzari AM; Giusto M; Tinelli C; Ascari E
Haematologica; 1997; 82(6):660-3. PubMed ID: 9499664
[TBL] [Abstract][Full Text] [Related]
29. [Effectiveness analysis of HA based triple-drug regimen as induction chemotherapy in the treatment of acute myeloid leukemia and its relationship with karyotype].
Mi YC; Xue YP; Yu WJ; Liu SH; Zhao YZ; Meng QX; Bian SG; Wang JX
Zhonghua Xue Ye Xue Za Zhi; 2005 Dec; 26(12):705-9. PubMed ID: 16620570
[TBL] [Abstract][Full Text] [Related]
30. Management of acute promyelocytic leukemia relapse in the ATRA era.
Castagnola C; Lunghi M; Corso A; Tajana M; Zappasodi P; Dabusti M; Lazzarino M; Bernasconi C
Haematologica; 1998 Aug; 83(8):714-7. PubMed ID: 9793255
[TBL] [Abstract][Full Text] [Related]
31. Idarubicin and cytosine arabinoside in the induction and maintenance therapy of high-risk myelodysplastic syndromes.
Invernizzi R; Pecci A; Rossi G; Pelizzari AM; Giusto M; Tinelli C; Ascari E
Haematologica; 1997; 82(5 Suppl):9-12. PubMed ID: 9402747
[TBL] [Abstract][Full Text] [Related]
32. Fludarabine, ARA-C, idarubicin and G-CSF (FLAG-Ida), high dose ARA-C and early stem cell transplant. A feasable and effective therapeutic strategy for de novo AML patients.
Clavio M; Gatto S; Beltrami G; Quintino S; Canepa L; Pierri I; Galbusera V; Carrara P; Miglino M; Varaldo R; Ballerini F; Venturino C; Cerri R; Risso M; Balleari E; Carella AM; Sessarego M; Ghio R; Bacigalupo A; Gobbi M
J Exp Clin Cancer Res; 2002 Dec; 21(4):481-7. PubMed ID: 12636093
[TBL] [Abstract][Full Text] [Related]
33. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
[TBL] [Abstract][Full Text] [Related]
34. [Preliminary treatment results of relapsed or refractory acute leukemia using two and three drug regimens].
Mariańska B; Apel D; Seferyńska I; Maj S
Wiad Lek; 1998; 51(1-2):42-5. PubMed ID: 9608830
[TBL] [Abstract][Full Text] [Related]
35. Mitoxantrone, etoposide, and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia: an Eastern Cooperative Oncology Group pilot study.
Tallman MS; Lee S; Sikic BI; Paietta E; Wiernik PH; Bennett JM; Rowe JM
Cancer; 1999 Jan; 85(2):358-67. PubMed ID: 10023703
[TBL] [Abstract][Full Text] [Related]
36. High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study.
Tedeschi A; Montillo M; Strocchi E; Cafro AM; Tresoldi E; Intropido L; Nichelatti M; Marbello L; Baratè C; Camaggi CM; Morra E
Cancer Chemother Pharmacol; 2007 May; 59(6):771-9. PubMed ID: 17256136
[TBL] [Abstract][Full Text] [Related]
37. Oral idarubicin in combination with cytosine-arabinoside in previously untreated patients with acute non-lymphocytic leukemia.
Falkson G; Coccia-Portugal MA; Vorobiof DA; Terblanche AP; Dreyer R
Am J Clin Oncol; 1986 Aug; 9(4):311-4. PubMed ID: 3463190
[TBL] [Abstract][Full Text] [Related]
38. [Analysis of chemotherapeutic results and prognostic factors of adult acute lymphoblastic leukemia].
Fu MW; Mi YC; Qiu LG; Yu WJ; Lin D; Bian SG; Wang JX
Zhonghua Xue Ye Xue Za Zhi; 2008 Jul; 29(7):435-40. PubMed ID: 19035173
[TBL] [Abstract][Full Text] [Related]
39. A randomized phase II study on the effects of 5-Aza-2'-deoxycytidine combined with either amsacrine or idarubicin in patients with relapsed acute leukemia: an EORTC Leukemia Cooperative Group phase II study (06893).
Willemze R; Suciu S; Archimbaud E; Muus P; Stryckmans P; Louwagie EA; Berneman Z; Tjean M; Wijermans P; Dohner H; Jehn U; Labar B; Jaksic B; Dardenne M; Zittoun R
Leukemia; 1997 Mar; 11 Suppl 1():S24-7. PubMed ID: 9130688
[TBL] [Abstract][Full Text] [Related]
40. Circulating immune complexes correlate with remission duration in acute myeloid leukemia.
Larson RA; Lukin CL; Daly KM; Mick R; Gore S; Le Beau MM
Leukemia; 1991 Feb; 5(2):131-7. PubMed ID: 2020195
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]